http://www.collective-evolution.com/2013/03/13/bee-venom-destroys-human-immunodeficiency-virus-hiv/Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving the surrounding cells unharmed. The research was conducted by the Washington University School of Medicine in St. Louis. The Nanoparticles carry melittin, which is the principal active component of bee venom. Melittin fuses with the HIV virus and destroys it’s protective envelope while molecular bumpers prevent the nanoparticles from harming the body’s normal cells. Bee venom is known to disrupt cellular walls and destroy tumour cells as well.
Bee venom contains a potent toxin called melittin that can poke holes in the protective envelope that surrounds HIV, and other viruses. Large amounts of free melittin can cause a lot of damage. Indeed, in addition to anti-viral therapy, the paper’s senior author, Samuel A. Wickline, MD, the J. Russell Hornsby Professor of Biomedical Sciences, has shown melittin-loaded nanoparticles to be effective in killing tumor cells.
The new study shows that melittin loaded onto these nanoparticles does not harm normal cells. That’s because Hood added protective bumpers to the nanoparticle surface. When the nanoparticles come into contact with normal cells, which are much larger in size, the particles simply bounce off. HIV, on the other hand, is even smaller than the nanoparticle, so HIV fits between the bumpers and makes contact with the surface of the nanoparticle, where the bee toxin awaits. (1)
Most anti-HIV drugs inhibit the virus’s ability to replicate. This is an anti-replication strategy that does nothing to stop the infection, and many strains of the virus have found ways around these drugs and continue reproducing. Given this discovery, a new vaginal gel could possibly be used in places where HIV is prominent. It can be used as a preventative measure to stop the initial infection and prevent the spread of HIV. The bee venom HIV study was published a several days ago in the journal Antiviral Therapy.
